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Abstract
Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis, is a bacterial pathogen that claims roughly 1.4 million
lives every year. Current drug regimens are inefficient at clearing infection, requiring at least 6 months of chemotherapy,
and resistance to existing agents is rising. There is an urgent need for new drugs that are more effective and faster acting.
The folate pathway has been successfully targeted in other pathogens and diseases, but has not yielded a lead drug against
tuberculosis. We developed a high-throughput screening assay against Mtb dihydrofolate reductase (DHFR), a critical
enzyme in the folate pathway, and screened a library consisting of 32,000 synthetic and natural product-derived
compounds. One potent inhibitor containing a quinazoline ring was identified. This compound was active against the wild-
type laboratory strain H37Rv (MIC99=207 mM). In addition, an Mtb strain with artificially lowered DHFR levels showed
increased sensitivity to this compound (MIC99=70.7 mM), supporting that the inhibition was target-specific. Our results
demonstrate the potential to identify Mtb DHFR inhibitors with activity against whole cells, and indicate the power of using
a recombinant strain of Mtb expressing lower levels of DHFR to facilitate the discovery of antimycobacterial agents. With
these new tools, we highlight the folate pathway as a potential target for new drugs to combat the tuberculosis epidemic.
Citation: Kumar A, Zhang M, Zhu L, Liao RP, Mutai C, et al. (2012) High-throughput Screening and Sensitized Bacteria Identify an M. tuberculosis Dihydrofolate
Reductase Inhibitor with Whole Cell Activity. PLoS ONE 7(6): e39961. doi:10.1371/journal.pone.0039961
Editor: Andrew J. Roe, University of Glasgow, United Kingdom
Received December 24, 2011; Accepted May 30, 2012; Published June 29, 2012
Copyright:  2012 Kumar et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported in part by grants from World Health Organization (A80533), the Ministry of Science and Technology of China (2009ZX09302-
001, 2010DFB73280 and 2012ZX09304-011), Novo Nordisk-CAS Research Fund, and the Paul G. Allen Family Foundation. The funders had no role in study design,
data collection and analysis, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: david.sherman@seattlebiomed.org (DRS); wangmw@mail.shcnc.ac.cn (MWW)
. These authors contributed equally to this work.
¤a Current address: Center of Traditional Medicine and Drug Research, Kenya Medical Research Institute, Nairobi, Kenya
¤b Current address: National Institute of Pharmaceutical Research and Development, Federal Ministry of Health, Idu Industrial Area, Garki, Abuja, Nigeria
Introduction
Tuberculosis (TB) has a long history in humans, with evidence
of TB-related deaths dating back to the 3
rd century BC [1].
Arguably one of the oldest and most destructive human diseases,
TB continues to be a massive burden on public health around the
world. The rise of AIDS (acquired immune deficiency syndrome),
and with it a population of people who are more susceptible to
opportunistic infections, has escalated the prevalence of TB.
Today, roughly 1.4 million people die every year from TB [2],
despite the availability of chemotherapies to combat the bacterium
that causes this disease (Mycobacterium tuberculosis, Mtb). The current
standard treatment for tuberculosis is a four-drug combination
therapy that lasts a minimum of 6 months [3]. In addition, several
factors have led to new strains of Mtb that are resistant to many or
sometimes all of the first and second line drugs [4]. Depending on
the drug susceptibility of the infecting strain, patients must endure
prolonged treatment with agents that are more expensive, more
toxic, and difficult to administer. The emergence of drug-resistant
Mtb adds even more urgency to the search for new therapeutics
that are better tolerated, more potent and efficacious at
eliminating Mtb infections in a shorter period of time, and also
highlights the importance of focusing on pathways and processes
in Mtb that are not the targets of existing medications. Recently,
there have been increased efforts to develop new and improved
therapeutics for tuberculosis, and this has led to a few promising
drug candidates [5]. However, it is essential that we continue to
develop a pipeline of new classes of compounds that are effective
against Mtb.
We have focused on the metabolic pathway of folate, which is a
critical nutrient in living organisms and is required for the transfer
of single-carbon units necessary for many biosynthetic reactions
[6,7]. Tetrahydrofolate (THF) and its derivatives are used as
cofactors in the production of thymidylate, purine bases, and some
amino acids, such as methionine - essential components of DNA,
RNA and protein synthesis. In Mtb dihydrofolate reductase
(DHFR) is an essential enzyme in this pathway, catalyzing the
reduction of dihydrofolate (DHF) into THF. Although DHFR has
been extensively studied as an effective drug target in several
pathogens and cancer cells, it has not been successfully targeted in
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inhibit Mtb DHFR in vitro but have no effect on the growth of live
Mtb [8]. However, the promise of this target in other systems has
prompted studies focused on developing antifolates that are active
against Mtb. These efforts were directed towards making analogs
of known DHFR inhibitors and exploiting differences in enzyme
structures to gain anti-Mtb properties [9,10,11]. In contrast, we
describe here the outcome of a high-throughput screening (HTS)
campaign targeting Mtb DHFR from which three small molecule
inhibitors were identified. Two of these were eliminated in
secondary screens, resulting in one compound with specific activity
against Mtb DHFR. This inhibitor was active against live Mtb
(MIC99=207 mM) and appeared to be on-target using a
recombinant strain engineered to produce less DHFR. The
compound contains a quinazoline ring moiety, a molecular
structure similar to the pteridine ring found in many classical
folate inhibitors, such as methotrexate. Our results demonstrate
the potential for discovery of active molecules to suppress Mtb
growth by targeting DHFR. They also underscore the promise of
screening large and diverse chemical libraries for novel DHFR
inhibitors, as well as the need to screen known DHFR inhibitors
more thoroughly for compounds with target-specific whole cell
activity. Better inhibitors with more potent on-target activity will
serve as tools to interrogate the feasibility of targeting DHFR as a
therapy for tuberculosis.
Methods
Isolation of Mtb Dihydrofolate Reductase (DHFR)
A pET28(a)
+-derived E. coli expression vector containing the
Mtb dfrA gene with a 6-histidine tag at the amino terminus of the
enzyme was generously provided by Dr. J. Sachettini (Texas A&M
University) [12,13]. Recombinant Mtb DHFR was expressed and
purified essentially as described [12,13], except that protein
expression was induced with 0.2 mM IPTG and harvested cells
were resuspended in 20 mM Tris-HCl pH 7.5, 100 mM NaCl,
1 mg/mL lysozyme and EDTA-free protease inhibitors (Sigma,
St. Louis, MO) and disrupted by sonication. His-tagged protein
was purified by metal affinity chromatography (His-Trap
TM from
Amersham, Bucks, UK) followed by size exclusion chromatogra-
phy (Sepharose 200, Amersham) according to the manufacturers’
instructions. Purified protein was concentrated to between 2–
10 mg/mL (20 mM Tris-HCl pH 7.5, 100 mM NaCl and 5%
glycerol) in centrifugal filtration units with a 10 kDa molecular
weight cutoff (EMD Millipore, Billerica, MA), flash frozen and
stored at -80uC.
Kinetic Assay of DHFR Activity
We used a low-throughput assay for DHFR activity that was
modified from previously described assays [14]. The assay
contained 0.2 mM NADPH, 10 mM DHF, 8.9 mM ß-mercapto-
ethanol, 150 mM KCl, 40.7 mM sodium phosphate at pH 7.4
and 125 ng/mL Mtb DHFR in a 50 mL volume. Absorbance of
NADPH was measured at 340 nm in a 384-well SpectraMax M2
microplate reader (Molecular Devices, Sunnyvale, CA). Activity
was calculated as the rate of change in absorbance at 340 nm.
Diaphorase-coupled Assay of DHFR Activity
The kinetic assay was performed as above, after which 10 mLo f
a solution containing diaphorase and resazurin was added to give a
final concentration of 0.75 U/mL and 0.2 mM, respectively.
Fluorescence intensity was measured on SpectraMax M2 micro-
plate reader (Molecular Devices) at an excitation of 560 nm and
emission of 590 nm. For the HTS campaign, fluorescent signal
was detected by an EnVision plate reader (PerkinElmer, Boston,
MA).
Counter-screening for Activity Against Diaphorase
Diaphorase was diluted to 0.075 U/mL and pre-incubated with
0.2 mM NADPH and varied concentrations of drug in a total
volume of 40 mL at room temperature for 5 minutes prior to
addition of 5 mL of resazurin to a final concentration of 0.2 mM.
After 10 minutes the fluorescence was measured as described
above.
Compound Library
The compound library consisted of 32,000 synthetic and natural
compounds and was composed of two sample sources: Novo
Nordisk A/S (Bagsværd, Denmark) and SPECS (Delft, Nether-
lands). The structural diversity covers heterocycles, lactams,
sulfonates, sulfonamides, amines, secondary amides and natural
product-derived compounds. The compounds were highly puri-
fied, and the stock was pre-solubilized in 100% DMSO prior to
application in the HTS campaign, performed with an average
concentration of 10 mM for each compound.
Mtb Strains
Mycobacterium tuberculosis H37Rv (ATCC 27294) was used as
the parent strain in all experiments. In addition, we constructed
a DHFR knockdown mutant Mtb in which dfrA expression is
regulated by levels of exogenously added tetracycline. Briefly,
we used PCR to produce and amplify a linear fragment
encoding (in order): a hygromycin resistance cassette, the
tetracycline regulator protein gene tetR driven by the constitutive
promoter tb21, and a truncated copy of Mtb dfrA driven by a
tetracycline regulated promoter Pmyc1tetO, which is repressed by
TetR in the absence of tetracycline [15]. Following electropo-
ration recombination of the linear DNA fragment into the Mtb
chromosome at the dfrA locus resulted in a single full length
copy of dfrA under the positive control of a tet-regulated
promoter along with a truncated and non-functional copy of
dfrA (ten amino acids at the carboxy-terminus were deleted).
Transformants (H37Rv:dfrA-TetON, referred to as DHFR kd)
were first selected for hygromycin resistance, and successful
recombination events were revealed by PCR (primers are listed
in Table 1). In the absence of tetracycline the tet promoter is
only weakly active, leading to reduced DHFR levels within cells.
The strain was maintained in the presence of 50 mg/mL of
hygromycin during routine culturing, but was grown in the
absence of hygromycin in all other studies detailed below.
Quantification of Mtb DHFR Transcript Levels
Quantitative PCR (qPCR) was used to determine the levels of
dfrA RNA in the Mtb strains used under various growth conditions.
Briefly, RNA was harvested as described previously [16] from
wild-type H37Rv and H37Rv:dfrA-TetON (DHFR kd) cultures
grown with varied levels of tetracycline (ATc). Twenty ng of total
RNA from each sample was employed to synthesize cDNA using
Invitrogen’s Superscript III kit (Carlsbad, CA) following the
manufacturer’s instructions. Subsequently, 5 mL of cDNA was
used in a two-step qPCR reaction [17]. An initial pre-amplification
step was performed with outer forward and reverse primers (all
primers are listed in Table 1) and Taq polymerase (Clonetech,
Mountain View, CA) with the following program: 95uC for 3
minutes, 15 cycles of 95uC for 20 seconds, 58uC for 1 minute, and
72uC for 1 minute, and a final step at 72uC for 7 minutes. The
second qRT-PCR reaction was performed using 0.1 mL of the
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primers, and 6FAM labeled MGB TaqMan probes (Applied
Biosystems, Foster City, CA). For each sample, the level of dfrA
transcript was normalized to that of sigA (locus tag: Rv2703)
generated from the same cDNA preparation.
Whole-cell Mtb Inhibition Assays
Mtb strains were grown in 7H9+/2 hygromycin to log phase
(OD600=0.3), diluted to a final OD600 of 0.002 and dispensed into
a 96-well round-bottom plate (Corning, Acton, MA) in a final
volume of 135 mL. To these cells 15 mL of compound diluted in
7H9 and 10% DMSO was added to yield 150 mL in each well at
the appropriate final concentration of drug in 1% DMSO (v/v).
For each strain, control wells containing no compound were used
as a measure of 100% growth, while wells containing a 1:100
dilution of the starting culture or 1.22 mM rifampicin (rif) were
used as a measure of 99% or 100% inhibition, respectively. Plates
were incubated at 37uC for 6 days, at which time they were
resuspended by pipetting and 20 mL of the total cell mixture was
used in a Bac-Titer Glo
TM (Promega, Madison, WI) assay of cell
viability, as per the manufacturer’s instructions. Luminescence
readings were conducted on a Fluo Star Omega plate reader
(BMG Lab Tech, Cary, NC). All values were measured from three
separate wells and averaged before calculating percent inhibition
using the following formula (RLUno drug – RLUsample)/(RLUno drug
– RLUrif). Data from dose-response experiments were analyzed
with Graphpad Prism
TM (San Diego, CA) and a non-linear least-
squares curve was generated to calculate the MIC99 for each
strain.
Results
Development of an HTS-compatible Single-time Point
Fluorescent Assay for DHFR
The DHFR reaction reduces dihydrofolate (DHF) into tetrahy-
drofolate (THF) while oxidizing the co-factor NADPH (Figure 1A).
NADPH has an absorbance at 340 nm allowing the enzymatic
activity of DHFR to be measured by monitoring the rate of
depletion of this substrate [14]. We used this kinetic assay to
confirm activity of the purified Mtb DHFR, to determine the
appropriate substrate and enzyme concentrations, and to optimize
other assay conditions. Initial titrations indicated that the rate of
the reaction is proportional to the amount of DHFR (Figure 1B).
However, this assay was not optimal for HTS since it depended on
a kinetic readout. Furthermore, small molecules often have
absorption spectra overlapping with that of NADPH, complicating
measurements and data analyses in that spectral range. Therefore,
we adapted the kinetic assay by linking the level of NADPH to a
second reaction with a fluorescent readout: the dark blue dye
resazurin can be reduced in an NADPH-dependent diaphorase
reaction into resorufin, a compound that is bright pink and
powerfully fluorescent. First, we titrated the amount of resazurin
and diaphorase in the coupling assay to allow a rapid reaction with
signal that was proportional to the concentration of NADPH
(Figure 1C). We then coupled the kinetic DHFR assay to this end-
point fluorescence assay (Figure 1D). The kinetic DHFR reaction
was initiated and allowed to proceed, depleting NADPH in
solution. After a defined incubation time diaphorase and resazurin
were added, causing a reduction of the dye by the remaining
NADPH. The kinetic assay was performed with 200 mM NADPH
in a 50 mL volume. After the addition of coupling reagents, the
final volume of the reaction was 60 mL with a maximal NADPH
concentration of 167 mM. As shown in Figure 1C, this was within
the linear detection range of the coupled reaction. Hence, the
fluorescence in the end-point assay was inversely proportional to
the activity of DHFR (Figures 1B and 1D). With no DHFR, the
fluorescence signal was high (corresponding to background levels
of NADPH depletion). When increasing amounts of DHFR were
present the rate of NADPH depletion increased, resulting in a
proportional drop in the final fluorescence intensity (Figures 1B
and 1D).
Assay Optimization and Validation for HTS
We tested the robustness of the coupled assay for translation
into an HTS format (Figure 2) using methotrexate (MTX, a potent
inhibitor of purified Mtb DHFR) as a control compound while
developing and validating the assay. We consistently found a good
dose response to MTX with an IC50 of 237 nM (Figure 2A). This
value exceeds the previously published value of 8.3 nM [14]
because relatively high substrate concentrations were used. Based
on these results we found that 5 mM MTX consistently resulted in
full inhibition of Mtb DHFR in this assay (Figures 2A and 2B).
Reactions performed with carrier DMSO alone were a measure
of full uninhibited Mtb DHFR activity, and served as a negative
control equivalent to 0% inhibition. Reactions performed in the
absence of Mtb DHFR were equivalent to complete inhibition and
served as positive controls (Figure 2B). Studies were repeated on
three separate days, with all mixes being freshly made, to evaluate
the variation between days. Plates were run with 2 sets of controls,
each with 16 replicates per plate. When performed in 384-well
plates a Z’ factor of 0.611 and S/B value of 4.31 were recorded
with CV values of 5.8% and 17.9% for the positive and negative
Table 1. List of primers used in this publication.
Target gene Primer type Forward sequence Reverse sequence Amplicon (bp)
Rv2763c (dfrA) outer cgaggaccaggcgcatttc tggcggctcagtacgacatttc 129
" inner catttccgggagatcaccat gcagcggccggacttta 85
" probe cacatgggattcgct
Rv2703 (sigA) outer aacctgcgcctggtggtttc ggtgatggcctggcgaatc 174
" inner cgcgcctacctcaaacagat cgtacaggccagcctcgat 91
" probe aaggtagcgctgctca
PCR validation of H37Rv:dfrA-TetON (DHFR kd)
thyA-hygR 59 site gtgccgttcaacatcgccag cagggattcttgtgtcacag 483
tetO-dfrA 39 site tcccggcgttgatctgtgcg ctcatgagcggtggtagctg 731
doi:10.1371/journal.pone.0039961.t001
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steps during the HTS campaign we used reactions conducted with
5 mM MTX as a positive control, since we had previously
established this as a proxy for reactions lacking enzyme. We
confirmed that the dynamic range and robustness of the assay
using these controls were very similar, yielding a Z’ factor of 0.687
and S/B value of 4.19 (Figure 2B). These statistical parameters
indicated that the assay met HTS requirements [18].
We also studied the stability of the reagents. At each time point
three sets of control reactions were performed: Mtb DHFR with no
inhibitor (DMSO alone), Mtb DHFR with 5 mM MTX, and the
negative control reaction in the absence of Mtb DHFR. Over 150
minutes we saw only very low levels of NADPH auto-oxidation
(2.42% loss as measured by a decrease in light absorbance at
340 nm; Figure S1). Similarly, we found that the magnitude of the
fluorescent signals for both the positive and negative control
reactions dropped very slightly, corresponding to the NADPH
auto-oxidation. However, the difference between the positive and
negative signals remained constant, indicating that the total
NADPH was still in sufficient excess and that the rate of the Mtb
DHFR reaction was not affected over the 150 minutes (Figure S1).
During the HTS campaign fresh solutions were prepared every 3
hours to ensure that the total NADPH present in solution was
sufficient.
HTS Campaign and Confirmation Studies
We then implemented an HTS campaign against a 32,000-
compound library. The screen was conducted over four days, with
25 plates screened per day. In each 384-well plate, one column on
each edge was reserved for positive (5 mM MTX) or negative
controls (DMSO). They showed good reproducibility across plates
and between different screening days (Figure 3). The CV between
all the control wells from the 100 plates was 6.4% and 12.2% for
the positive and negative controls, respectively. Inhibition of Mtb
DHFR was calculated from the controls within each individual
plate. In the initial screen, 52 ‘hits’ (0.16%) displayed greater than
30% inhibition (Figure 3). Selected hits were re-screened at a
concentration of 10 mM and three compounds consistently
inhibited Mtb DHFR activity in this assay. Confirmed hits
(0.01%) were further tested for concentration-dependent response
characteristics (Figure S2.A). All three compounds exhibited
inhibition in a dose-dependent manner and were further examined
in the counter-screen for activity against the coupling enzyme,
diaphorase (Figure S2.B). Two of the compounds inhibited
diaphorase, indicating that their activity was not specific for
DHFR. NC00094221 (inset in Figure 4A) had no inhibitory
activity against the counter-screen. All three compounds were next
evaluated in the low-throughput assay against Mtb DHFR. As
expected, the two inhibitors active in the counter-screen were not
Figure 1. Development of a single-time point assay with a diaphorase-coupled fluorescence readout. A. Reaction schematic. Reaction 1:
DHFR, in a NADPH-dependent reaction, converts dihydrofolate (DHF) to tetrahydrofolate (THF), causing a depletion of reduced NADPH. Reaction 2:
Diaphorase utilizes NADPH that was unused from the DHFR reaction to generate fluorescence. Enzymes are italicized and bold. B. Kinetic NADPH-
depletion assay. The rates of NADPH depletion in reactions performed with 200 mM NADPH, 0.2 mM DHF and varied levels of DHFR were monitored
by measuring absorbance at 340 nm. C. Fluorescence coupling. The fluorescence generated after 4 minutes of incubating diaphorase and resazurin
with various concentrations of NADPH were measured. D. End-point fluorescence assay. The NADPH-depletion assay run as in (B) was coupled to
diaphorase and resazurin after 30 minutes, and the resulting fluorescence measured at excitation and emission wavelengths of 560 and 590 nM,
respectively.
doi:10.1371/journal.pone.0039961.g001
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specific activity against Mtb DHFR, with an estimated IC50 of
22.4 nM. In comparison, MTX showed an IC50 of 5.1 nM
(Figure 4A).
In-vitro Activity Against Live Mtb
After establishing the activity of NC00094221 against purified
recombinant enzyme, we sought to determine if it could inhibit the
growth of whole-cell Mtb. We also wanted to address two factors
complicating our ability to interpret results of tests performed on
wild-type Mtb: the possibility that compounds were unable to pass
through the cell wall as well as the potential off-target effect. As
described earlier, many inhibitors with potent activity against
purified recombinant Mtb DHFR such as MTX fail to show
activity in whole cells. If compound penetration was poor, then
medicinal chemistry might be employed to increase intracellular
concentrations. However, the in vivo target would still be unclear.
We reasoned that a strain with artificially lowered enzyme could
address both issues of cell permeability and target specificity
[19,20]. Lowering the levels of DHFR would sensitize bacteria to
folate pathway inhibitors and conversely we would expect wild-
type Mtb to be more resistant to inhibition by the same
concentration of an active compound.
The use of tetracycline derivatives to regulate gene expression
has been well studied in bacteria and has been successfully adapted
for mycobacterial gene regulation [15]. We utilized a single-cross
over homologous recombination strategy to replace the wild-type
promoter of Mtb dfrA with a tetracycline regulated promoter,
which yielded the partial merodiploid strain H37Rv:dfrA-TetON
(DHFR kd) containing a full length Mtb DHFR under the positive
control of anhydro-tetracycline (ATc). DHFR kd exhibited only a
very slight growth defect in vitro that was rescued when cultured in
the presence of ATc (data not shown). We measured dfrA
transcript levels in this strain under varied growth conditions
(Figure 4B). Without ATc, levels of dfrA transcript were 2.8-fold
lower than that of wild-type Mtb, but in the presence of 100 ng/
mL ATc transcription of dfrA increased by 3.9-fold (Figure 4B).
DHFR kd should be hypersusceptible only to inhibitors that target
the folate pathway. We determined that there was no significant
change in the MIC99 of isoniazid (INH) between the two strains
(Figure 4D), which targets cell wall synthesis [21]. However, using
a previously published inhibitor of Mtb DHFR, WR99210 [10], we
showed that in the absence of ATc DHFR kd is approximately
three times more susceptible to growth inhibition compared with
H37Rv (Figure 4D). Further studies with DHFR kd confirmed that
MTX, while barely active against wild-type Mtb, had more
convincing concentration-dependent whole-cell inhibitory activity
in the DHFR-sensitized strain (Figure 4C). The MIC99 of MTX
against wild-type Mtb was over 3-fold higher than against the
sensitized strain (Figure 4D), suggesting that it targets DHFR or
the folate pathway in live cells. We then tested the active
compound identified from our primary screen for activity on
DHFR kd. We found that the potency of NC00094221 increased
by about 3-fold in the knockdown strain (MIC99 of 207 mMi n
H37Rv vs. MIC99 of 70.7 mM in DHFR kd; Figures 4C and 4D),
demonstrating that DHFR or a related enzyme in the folate
pathway is the relevant intracellular target of this compound.
Discussion
Reduced folate is a critical nutrient in living organisms, and
disruption of the folate pathway is widely exploited for chemo-
therapy [6,22]. Dihydrofolate reductase is one of the most
commonly studied enzymes in the folate pathway and is a well-
Figure 2. Confirming the robustness of the assay for HTS. A.
Standard curve of methotrexate (MTX). The concentration-dependent
inhibitory activity of MTX was measured in the coupled assay. B.
Statistical Factors. Sixteen replicates of each control reaction were
performed in the optimized assay conditions. High-throughput
screening (HTS) parameters, including Z’-factor (Z’) and signal to
background ratio (S/B) were studied. Raw fluorescence units (right Y-
axis) from each of the controls and % inhibition (left Y-axis) are shown.
The (-) DHFR controls were used as a measure of complete inhibition, in
order to calculate % inhibition.
doi:10.1371/journal.pone.0039961.g002
Figure 3. Primary screening. A collection of 32,000 compounds
were tested against the optimized DHFR assay at a final concentration
of 10 mM. Sixteen positive (5 mM MTX shown in pale grey symbols) and
negative (DMSO alone shown in dark grey symbols) control reactions
were plated on each of the 100 screening plates in order to calculate %
inhibition. Controls from the entire screening are shown clustered
together. An initial threshold for hits was set at 30% inhibition (dashed
line).
doi:10.1371/journal.pone.0039961.g003
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inhibitor of DHFR, has historically been prescribed to treat
cancers and skin diseases [6]. Pyrimethamine and trimethoprim,
also inhibitors of DHFR, are more selective for protozoal and
bacterial DHFR, respectively, compared to the human enzyme,
and have routinely been applied to treat malaria and as general
antimicrobials [6,23]. The efficacy of these therapeutics and their
analogs is enhanced in combination with agents that target
dihydropteroate synthetase (DHPS), another folate pathway
enzyme that is unique to prokaryotes [8]. While these combina-
tions have not yet yielded a treatment for tuberculosis, they are
potent against Mycobacterium avium and Mycobacterium leprae, two
close relatives of Mtb [24]. Clearly, an opportunity exists to
develop an active inhibitor of Mtb DHFR with clinical value
against tuberculosis.
Several groups have adapted previously discovered DHFR
inhibitors in an effort to improve selectivity for Mtb DHFR and to
increase potency against live Mtb [10,11]. A parallel approach
would be to find active molecules with novel chemical structures.
This would provide a broader base of scaffolds to be used as
starting points for drug discovery. To this end, we developed an
HTS-compatible assay to search for novel inhibitors of Mtb
DHFR. It was employed to screen a compound library of 32,000
synthetic and natural molecules. Of the hits identified and
confirmed, NC00094221 demonstrated a dose-dependent inhibi-
tion on the purified recombinant Mtb DHFR (IC50=22.4 nM), as
well as DHFR-specific growth suppression of live Mtb, displaying
an MIC99 of 207 mM.
NC00094221 belongs to the diaminoquinazoline family of
compounds, and its characterization as an Mtb DHFR inhibitor
Figure 4. Characterization of NC00094221. A. Dose-response curves in low-throughput Mtb DHFR enzyme assay. NC00094221 (chemical
structure shown inset into the graph) and MTX were tested at varied concentrations in the kinetic assay performed with 10 mM DHF and 125 ng/mL
recombinant DHFR. Data were fitted to a non-linear least-squares curve and IC50 values were calculated using GraphPad Prism
TM.B. Quanitification of
DHFR transcript levels in a recombinant Mtb strain. The levels of DHFR transcript were assayed by qRT-PCR in wild-type Mtb strain H37Rv (wt- pale
grey bar) and the engineered Mtb strain (H37Rv:dfrA-TetON, referred to as DHFR kd- dark grey bars) in the presence of varied levels of tetracycline
(ATc). DHFR transcript levels from each sample were first normalized to SigA transcript levels and then shown as the fold change when compared to
wild-type (wt) Mtb. C. Live Mtb growth inhibition assay. Varied concentrations of methotrexate (MTX, white symbols) or NC00094221 (black symbols)
were incubated with wild-type Mtb (triangles) or the DHFR kd (circles) and grown for 6 days prior to assessment of cell growth using the
commercially available Bactiter-Glo assay kit. For each strain, controls including wells with no drug (DMSO carrier was added instead), 1.22 mM
rifampicin (106MIC99) and a 1/100 dilution of the starting culture were used to calculate 0%, 100% and 99% inhibition, respectively. Data were fitted
to a non-linear least-squares curve and MIC99 calculations were performed using GraphPad Prism
TM. D. Target-specific drug sensitivity in DHFR kd.
The sensitivity of the wild-type Mtb and DHFR kd was tested against various inhibitors and displayed as the ratio of a compound’s MIC99 when
measured in wild-type Mtb over the MIC99 measured in DHFR kd in the absence of ATc.
doi:10.1371/journal.pone.0039961.g004
Mtb DHFR HTS Identifies Whole Cell Inhibitor
PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e39961from this library is consistent with previous research that identified
many classical folate inhibitors containing quinazoline rings [25].
The latter are related to pteridine rings seen in both the DHFR
substrate, dihydrofolate, and the drug, MTX. When compared to
MTX, NC00094221 showed weaker inhibition of the purified Mtb
enzyme (NC00094221 IC50=22.4 nM vs. MTX IC50=5.1 nM,
Figure 4A). However, NC00094221 was more potent against
whole-cell Mtb (Figure 4C). Our results confirmed that this activity
was directed at the folate pathway in live Mtb since the dfrA
knockdown strain was more susceptible (Figures 4C and 4D). In
addition, a previous study identified this chemical structure as an
active inhibitor of the DHFR enzymes isolated from P. carinii
(IC50=2.7 mM) and T. gondii [25], but its potency against Mtb
DHFR or whole-cell Mtb was not reported. These data suggest
that a more thorough search of other previously identified
antifolates may reveal potent antiymcobacterial agents with
DHFR-specific activity.
While previously identified inhibitors of the Mtb DHFR enzyme
such as WR99210 and its analogs have displayed on-target activity
against live Mtb [10], they proved unsuitable for testing in animals
because of high toxicity to host cells. Thus, the challenge has been
to find a compound with high specificity for Mtb DHFR that has
little or no activity against the human enzyme. Our work indicates
that a more thorough analysis of known antifolates might be a
valuable method in the search for DHFR-specific antimycobacter-
ial agents. It also underscores the value of target-based whole-cell
assays using knockdown strains for identifying compounds with
potent on-target activity against live pathogens such as Mtb. Many
potent enzyme inhibitors fail in whole-cell assays, in part due to
their poor permeability through the notoriously waxy outer coat of
Mtb. Evaluating compounds against wild-type Mtb alone sets a
high bar for compounds that may have limited cell entry. It also
removes from consideration compounds that have specific activity
against the enzyme but possess weak or no activity against the
whole cell. Conversely, determining the ability of compounds to
modulate the growth of Mtb made hyper-susceptible to DHFR
inhibition permits us to identify weaker molecules, thereby gaining
valuable information concerning structure-activity relationship to
assist the design of effective drug leads against Mtb. With the
growing demand for better anti-tuberculosis agents, it is incum-
bent on us to pursue diverse avenues of drug discovery. Focusing
on an area such as the folate pathway, with its rich history of
successful drugs, is therefore a promising way forward.
Supporting Information
Figure S1 Stability of assay reagents. A single batch of
reagents was used in the HTS assay at 0, 50, 100 and 150 minutes
(8 wells for each control) after having been freshly prepared and
left at room temperature. The mean at each time point as well as
the average of the measurements over 150 minutes. (32 replicates
total) are plotted.
(TIF)
Figure S2 A. Dose response curve in primary HTS assay. The
dose-response characteristics of the three hits identified from the
library were studied in the diaphorase-coupled enzyme assay.
Methotrexate (MTX) was used as a positive control. B. Counter-
screening. The activity of the three hits were tested against the
coupling enzyme (diaphorase) used in the high-throughput screen
(HTS). Only NC00094221 did not inhibit the counter-screen.
(TIF)
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